Conventional antipsychotic medications for schizophrenia.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Schizophrenia bulletin

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1093/SCHBUL/21.4.567PMID 8749885
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Clinical Guide for the Treatment of Schizophrenia

  2013cited by this paper
• Prophylactic effect of neuroleptics in symptom-free schizophrenics: A comparative dose-response study of haloperidol and propericiazine

  2004cited by this paper
• Antipsychotic drugs: is more worse? a meta-analysis of the published randomized control trials

  1994cited by this paper
• MAINTENANCE ANTIPSYCHOTIC MEDICATION

  1993cited by this paper
• Psychopharmacologic treatment of schizophrenia.

  1993cited by this paper
• Antipsychotic Drugs and their Side-Effects

  1993cited by this paper
• Time course and biologic correlates of treatment response in first-episode schizophrenia.

  1993cited by this paper
• Ideal and Reality of Neuroleptic Relapse Prevention

  1992cited by this paper
• Dosage of haloperidol for schizophrenia.

  1991cited by this paper
• Maintenance medication for schizophrenia: strategies for dose reduction.

  1991cited by this paper
• An Empirical Comparison of Meta-Analytic and Traditional Reviews

  1991cited by this paper
• Maintenance Medication for Schizophrenia: Strategies for Dose Reduction

  1991cited by this paper
• Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.

  1991cited by this paper
• Continuous versus targeted medication in schizophrenic outpatients: outcome results.

  1990cited by this paper
• Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients.

  1990cited by this paper
• A controlled dose comparison of haloperidol in newly admitted schizophrenic patients.

  1990cited by this paper
• Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment.

  1990cited by this paper
• Innovations in the Psychopharmacologic Treatment of Schizophrenia

  1989cited by this paper
• Acute treatment response and short term outcome in schizophrenia: first results of the NIMH treatment strategies in schizophrenia study. Treatment Strategies in Schizophrenia Collaborative Study Group.

  1989cited by this paper
• Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study.

  1988cited by this paper
• Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses.

  1988cited by this paper
• Experimental comparison of the effectivity of individually adapted and standardized dosages of haloperidol.

  1987cited by this paper
• Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome.

  1987cited by this paper
• Psychopharmacology : the third generation of progress

  1987cited by this paper
• Double-Blind Comparison of Half-Dose and Standard-Dose Flupenthixol Decanoate in the Maintenance Treatment of Stabilised Out-Patients with Schizophrenia

  1987cited by this paper
• The natural course of schizophrenia and effective maintenance drug treatment.

  1986cited by this paper
• Depot neuroleptics: a comparative review of standard, intermediate, and low-dose regimens.

  1986cited by this paper
• High-dose versus low-dose strategies in the treatment of schizophrenia.

  1985cited by this paper
• Minimal maintenance medication: effects of three dose schedules on relapse rates and symptoms in chronic schizophrenic outpatients.

  1983cited by this paper
• Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates.

  1983cited by this paper
• Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients.

  1981cited by this paper
• Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients.

  1981cited by this paper
• Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride.

  1979cited by this paper
• Depot fluphenazine in the prevention of relapse in schizophrenia: evaluation of a treatment regimen [proceedings].

  1979cited by this paper
• Drug and family therapy in the aftercare of acute schizophrenics.

  1978cited by this paper
• A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia

  1978cited by this paper
• Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year.

  1977cited by this paper
• Prevention of recidivism of schizophrenics treated with fluphenazine enanthate.

  1975cited by this paper
• Controlled Trial of Depot Fluphenazine in Out-patient Schizophrenics

  1974cited by this paper
• Comprehensive Textbook of Psychiatry

  1968cited by this paper

• Effectiveness of Cognitive and Behavioral Interventions in the Treatment of Schizophrenia: An Umbrella Review of Meta-Analyses

  2025cites this paper
• The development of paliperidone nanocrystals for the treatment of schizophrenia

  2024cites this paper
• Oral Health Status and Factors Related to Oral Health in Patients with Schizophrenia: A Matched Case-Control Observational Study

  2024cites this paper
• Suicidality and use of psychotropic medications in patients with schizophrenia: a prospective cohort study

  2024cites this paper
• Exploring the unconventional: health professionals’ experiences into medication-free treatment for patients with severe mental illness

  2024cites this paper
• O uso de clozapina e outros antipsicóticos em esquizofrenia resistente nos centros de atenção psicossocial de João Pessoa, PB, Brasil

  2023cites this paper
• Beta-2 adrenergic receptor agonism alters astrocyte phagocytic activity and has potential applications to psychiatric disease

  2023cites this paper
• Oral hygiene status and factors related to oral health in hospitalized patients with schizophrenia.

  2022cites this paper
• Pharmacotherapy of Schizophrenia in Acute and Maintenance Phase

  2021cites this paper
• Adherence to Antipsychotic Drugs by Medication Possession Ratio for Schizophrenia and Similar Psychotic Disorders in the Republic of Korea: A Retrospective Cohort Study

  2020cites this paper
• Cultural Considerations for Schizophrenia Spectrum Disorders II: Assessment and Treatment

  2020cites this paper
• Treatment and Management

  2020cites this paper
• Clinical outcomes in a large registry of patients with major depressive disorder treated with Transcranial Magnetic Stimulation.

  2020cites this paper
• Early Repolarization Pattern is Associated with Schizophrenia: A Single Center Experience in Japan

  2020cites this paper
• Clinical Characteristics, Drug Adherence to Antipsychotics and Medical Use Trends in Patients First Diagnosed with Psychotic Disorder: A Preliminary Study

  2019cites this paper
• Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials

  2019cites this paper
• Medisinfri behandling – et omstridt og etterlengtet tilbud

  2018cites this paper
• Psikiyatri Polikliniği: Şizofreni Tedavisi Bağlamında Kesitsel Bir Çalışma

  2018cites this paper
• Connectivity Analyses of Bioenergetic Changes in Schizophrenia: Identification of Novel Treatments

  2018cites this paper
• Assessment of Cognition in Schizophrenia Using Trail Making Test: A Meta-Analysis

  2018cites this paper
• Socio-demographic correlates of treatment response among patients with schizophrenia in a tertiary hospital in South-East Nigeria.

  2017cites this paper
• Effect of bumetanide, a selective NKCC1 inhibitor, on hallucinations of schizophrenic patients; a double-blind randomized clinical trial.

  2017cites this paper
• Clinical Correlates of Treatment Response among Patients with Schizophrenia in a Tertiary Nigerian Hospital

  2017cites this paper
• Prevalence and correlates of antipsychotic polypharmacy among outpatients with schizophrenia attending a tertiary psychiatric facility in Nigeria

  2017cites this paper
• Psychotropic prescriptions for the treatment of schizophrenia in an outpatient clinic.

  2017cites this paper
• Appropriateness of antipsychotic drugs prescribed for First episode psychosis by clinicians at Chainama Hills college hospital in Lusaka

  2017cites this paper
• Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.

  2017cites this paper
• Bifeprunox versus placebo for schizophrenia.

  2016cites this paper
• The Benefits of Antipsychotic Drugs: Symptom Control and Improved Quality of Life

  2016cites this paper
• Determination of antipsychotic drugs in hospital and wastewater treatment plant samples by gas chromatography/tandem mass spectrometry.

  2016cites this paper
• Using early antipsychotic response to predict treatment outcome in patients with first-episode psychosis

  2016cites this paper
• Atypical psychotic symptoms and Dandy–Walker variant

  2016cites this paper
• INTERNATIONAL JOURNAL OF PHARMACY & LIFE SCIENCES

  2015cites this paper
• The role of cognitive control in memory retrievalapplications to schizotypy and schizophrenia

  2015cites this paper
• Farmakoekonomiczna ocena kosztów terapii osób ze zdiagnozowaną schizofrenią leczonych farmakologicznie oraz w skojarzeniu z terapią niefarmakologiczną

  2015cites this paper
• Rice bran oil prevents neuroleptic-induced extrapyramidal symptoms in rats: Possible antioxidant mechanisms

  2015cites this paper
• Prescription for Critical Thinking: A Discussion of Psychotropic Medication and Counseling

  2015cites this paper
• Evaluation of the pharmacokinetics, safety and clinical efficacy of ziprasidone for the treatment of schizophrenia and bipolar disorder

  2015cites this paper
• Is non-pharmacological treatment an option for certain schizophrenia patients?

  2014cites this paper
• William T. Carpenter Jr: 35 years of clinical trials.

  2014cites this paper
• L'association clozapine avec un autre antipsychotique dans le traitement de la schizophrénie hyper-résistante : analyse des pratiques de prescription au travers d'une étude observationnelle

  2014cites this paper
• Acute treatment of schizophrenia: introduction to the Word Federation of Societies of Biological Psychiatry guidelines.

  2014cites this paper
• Clozapine Combinations in Treatment-Resistant Schizophrenia Patients

  2013cites this paper
• Strošek In Učinkovitost Zdravljenja Shizofrenije Z Atipičnimi Antipsihotiki V Sloveniji: Raziskava Stroškovne Učinkovitosti / The Cost And Effects Of Atypical Antipsychotic Agents In Patients With Schizophrenia In Slovenia: A Cost Effectiveness Study

  2013cites this paper
• PORT Recommended Oral Antipsychotic Dosage Ranges for the Treatment of Schizophrenia First Generation Antipsychotic Medication PORT Recommended Dosage

  2013cites this paper
• Guideline-concordant antipsychotic use and mortality in schizophrenia.

  2013cites this paper
• Treatment-Resistant Schizophrenia: Prevalence and Risk Factors

  2013cites this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects

  2013cites this paper
• Problems with non-adherence to antipsychotic medication in Samoan new Zealanders: A literature review

  2012influential citation
• Development of a core set of performance measures for evaluating schizophrenia treatment services.

  2012cites this paper
• Amisulpride

  2012cites this paper
• Antipsychotic medicines in Australian community practice: Effectiveness, adverse effects and quality of life for people with schizophrenia

  2012cites this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance

  2012influential citation
• Antipsychotic medication for early episode schizophrenia.

  2011cites this paper
• Neural correlates of cognitive impairment in schizophrenia

  2011cites this paper
• Prescribing habits in the pharmacotherapy of schizophrenia

  2011cites this paper
• The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

  2010cites this paper
• Dopamine Receptors and the Treatment of Schizophrenia

  2010cites this paper
• Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients.

  2010cites this paper
• Basurto-IGPP. A manual-directed approach of integrative group psychotherapy in psychosis.

  2010cites this paper
• Basurto-PGIP: Un abordaje manualizado de psicoterapia grupal.

  2010cites this paper
• Erratum to: Identifying, Assessing, and Treating Early Onset Schizophrenia at School

  2010cites this paper
• The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.

  2010cites this paper
• Use and Safety of Antipsychotic Drugs During Pregnancy

  2009cites this paper
• Antipsychotic-induced oxidative stress in Rat Brain

  2009cites this paper
• SODELOVANJE BOLNIKOV S SHIZOFRENIJO PRI ZDRAVLJENJU Z ANTIPSIHOTIKI ADHERENCE TO ANTIPSYCHOTIC MEDICATION IN SCHIZOPHRENIA PATIENTS

  2009cites this paper
• An Investigation of Depression and Loneliness among School Principals

  2009cites this paper
• Evaluation and medication therapy for treatment resistance in schizophrenia

  2009cites this paper
• Leitlinienbasierte Therapie der Schizophrenie

  2009cites this paper
• PSYCHOSIS AND SCHIZOPHRENIA

  2009cites this paper
• Adherence to antipsychotic medication in schizophrenia patients.

  2009cites this paper
• Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study

  2008cites this paper
• 정신장애인의 배우자 태도와 재발의 인과적 관계에 관한 탐색

  2008cites this paper
• Antipsychotic drugs increase N‐acetylaspartate and N‐acetylaspartylglutamate in SH‐SY5Y human neuroblastoma cells

  2008cites this paper
• Serotonin(1A) receptor agonism in the expression of behavioral dopaminergic supersensitivity in subchronic haloperidol treated rats.

  2008cites this paper
• Verbesserung kognitiver Leistungen bei chronischer Schizophrenie durch rekombinantes humanes Erythropoietin (rhEPO)

  2008influential citation
• Effect of antipsychotics on creatine kinase activity in rat brain.

  2007cites this paper
• Electroencephalographic and Immunological Findings in Patients with Schizophrenia Treated with Clozapine

  2007cites this paper
• Effect of antipsychotics on succinate dehydrogenase and cytochrome oxidase activities in rat brain

  2007cites this paper
• Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.

  2007cites this paper
• Aripiprazole: effectiveness and safety under naturalistic conditions.

  2007cites this paper
• Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment

  2007cites this paper
• Reducing polypharmacy through the introduction of a treatment algorithm: use of a treatment algorithm on the impact on polypharmacy.

  2006cites this paper
• Associations Between Adherence to Guidelines for Antipsychotic Dose and Health Status, Side Effects, and Patient Care Experiences

  2006cites this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia

  2006cites this paper
• [Duration and principles of the prescription of neuroleptics in maintain therapy].

  2006cites this paper
• Psychosocial Acute Treatment in Early-Episode Schizophrenia Disorders

  2006cites this paper
• Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 2: tratamento de longo prazo

  2006cites this paper
• Statistical benchmarks for process measures of quality of care for mental and substance use disorders.

  2006cites this paper
• Predicting Medication-Free Treatment Response in Acute Psychosis: Cross-Validation From the Finnish Need-Adapted Project

  2006cites this paper
• Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride

  2006cites this paper
• Validation of the tremulous jaw movement model for assessment of the motor effects of typical and atypical antipychotics: effects of pimozide (Orap) in rats.

  2005cites this paper
• Clinical practice guidelines. Treatment of schizophrenia.

  2005cites this paper
• Implementing research findings into practice using clinical opinion leaders: barriers and lessons learned.

  2005cites this paper
• COMPARATIVE EFFICACY OF EVERY 2 WEEKS VERSUS EVERY 6 WEEKS INJECTIONS OF FLUPHENAZINE DECANOATE

  2005cites this paper
• Predicting Drug-Free Treatment Response in Acute Psychosis From the Soteria Project by

  2005cites this paper
• Performance measures for early psychosis treatment services.

  2005cites this paper
• Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia.

  2005cites this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia

  2005influential citation
• Slow Transcranial Magnetic Stimulation Can Rapidly Reduce Resistant Auditory Hallucinations in

  2005cites this paper